Lexology September 4, 2024
McGuireWoods Consulting LLC

Click here to listen to the audio.

A revolution in the use of psychedelic drugs to treat mental health issues experienced a setback in early August when the FDA declined to approve MMDA as a treatment for post-traumatic stress disorder.

Host Stephanie Kennan provides important context to the FDA’s decision, which...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, FDA, Govt Agencies, Mental Health, Pharma, Pharma / Biotech, Provider, Trends
The Keys to Better Mental Healthcare in 2025? Precision, Personalization, and Progress
Embark Behavioral Health Parts with 3 C-Suite Members to Shift Resources to its Programs
How this health system builds its own behavioral health workforce
3 Ways ‘Rejection Sensitivity’ Ruins Your Mental Health—By A Psychologist
Why beds at this new behavioral health hospital are empty

Share This Article